Activatable Enzymatic Nanoplatform Incorporated into Microneedle Patch for Relieving Tumor Hypoxia Augmented Photodynamic Therapy
© 2025 Wiley‐VCH GmbH.
| Veröffentlicht in: | Advanced materials (Deerfield Beach, Fla.). - 1998. - 37(2025), 39 vom: 01. Okt., Seite e2504258 |
|---|---|
| 1. Verfasser: | |
| Weitere Verfasser: | , , , , , , |
| Format: | Online-Aufsatz |
| Sprache: | English |
| Veröffentlicht: |
2025
|
| Zugriff auf das übergeordnete Werk: | Advanced materials (Deerfield Beach, Fla.) |
| Schlagworte: | Journal Article activatable enzymatic activity cancer treatment microneedle patch traceable photodynamic therapy tumor microenvironment Photosensitizing Agents Catalase EC 1.11.1.6 Chlorophyllides mehr... |
| Zusammenfassung: | © 2025 Wiley‐VCH GmbH. The clinical advancement of photodynamic therapy (PDT) faces entrenched impediments, particularly the suboptimal solubility of hydrophobic photosensitizers (PSs) and tumor-associated hypoxia. Herein, a universally applicable, carrier-free nanotherapeutic platform is devised in which catalase (CAT) functions dually as a biocatalytic oxygenator and a biocompatible scaffold for PSs encapsulation. Through self-assembly with diverse hydrophobic PSs-including 2-(1-hexyloxyethyl)-2-divinyl-pyropheophorbide-a (HPPH), chlorin e6 (Ce6), and zinc (II)-phthalocyanine (ZnPc)-CAT forms uniform and stable PSCAT nanoparticles (NPs), obviating the necessity for supplementary nanocarriers. These nanostructures are embedded within microneedle (MN) patches, facilitating minimally invasive, spatially targeted transdermal administration. The PSs bind to the hydrophobic pocket of CAT within NPs, temporarily suppressing its bioactivity, which is restored upon NPs disassembly in the acidic tumor microenvironment (TME). This pH-responsive "OFF-to-ON" mechanism orchestrates the synchronized release of PSs and reactivation of CAT, which catalyzes endogenous hydrogen peroxide (H₂O₂) to generate oxygen (O2), alleviating hypoxia and augmenting O2 availability for PDT. In vivo validation in a 4T1 murine mammary carcinoma model corroborated this approach's therapeutic superiority and biocompatibility. Collectively, the findings delineate a minimalist, multifunctional strategy to simultaneously enhance the bioavailability of PSs and overcome hypoxia in PDT for more efficacious oncologic therapy |
|---|---|
| Beschreibung: | Date Completed 08.10.2025 Date Revised 08.10.2025 published: Print-Electronic Citation Status MEDLINE |
| ISSN: | 1521-4095 |
| DOI: | 10.1002/adma.202504258 |